Orlando, 26 June 2010: Linagliptin, a dipeptidyl dipeptidase (DPP)-4 inhibitor being developed by Boehringer Ingelheim, achieves significant reductions in blood glucose in patients with type 2 diabetes both as monotherapy and in combination with other commonly used hypoglycaemic agents, according to four phase III trials reported at the American Diabetes Association meeting (25-29 June 2010, Orlando, Florida).
The studies randomised patients with type 2 diabetes failing to meet target blood glucose levels with their current therapy to linagliptin (5mg once daily) or placebo, in addition to dietary advice or other therapy. In the monotherapy trial, patients treated with linagliptin showed a mean reduction in HbA1c of 0.69% compared to placebo (p